Managed Healthcare Executive December 10, 2021
2021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA. Take a look at Managed Healthcare Executive’s top four biosimilar developments of 2021.
2021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA.
Here are Managed Healthcare Executive®’s top five biosimilar developments of 2021:
1. FDA’s approval of the first biosimlar and interchangeable insulin
In August, the FDA approved Semglee (reference product Lantus), the first biosimilar and interchangeable insulin. That decision is expected to save the U.S. healthcare system “hundreds...
Today's Sponsors
Today's Sponsor